This study aims to evaluate the oncological and functional outcome of bilateral versus unilateral template resection in patients with postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for non-seminoma. METHODS: Between 2003 and 2018, 504 RPLNDs have been performed in 434 patients. The database of consecutive patients was queried to identify 171 patients with PC-RPLND after 1st line chemotherapy for a non-seminoma with or without bilateral template resection. Re-Dos, late relapse, salvage patients and thoracoabdominal approaches were excluded. Indication for a template resection was a unilateral residual mass mainly less than 5 cm as published (Heidenreich et al. 2009). Descriptive statistics were used to report preoperative features, post-operative outcomes and patterns of recurrence. Kaplan-Meier analyses were used to describe recurrence-and cancer specific mortality-free survival rates.
INTRODUCTION AND OBJECTIVES:
This study aims to evaluate the oncological and functional outcome of bilateral versus unilateral template resection in patients with postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for non-seminoma. METHODS: Between 2003 and 2018, 504 RPLNDs have been performed in 434 patients. The database of consecutive patients was queried to identify 171 patients with PC-RPLND after 1st line chemotherapy for a non-seminoma with or without bilateral template resection. Re-Dos, late relapse, salvage patients and thoracoabdominal approaches were excluded. Indication for a template resection was a unilateral residual mass mainly less than 5 cm as published (Heidenreich et al. 2009 ). Descriptive statistics were used to report preoperative features, post-operative outcomes and patterns of recurrence. Kaplan-Meier analyses were used to describe recurrence-and cancer specific mortality-free survival rates.
RESULTS: 90 and 81 patients underwent unilateral and bilateral resection, respectively. Median size of residual mass was 7 cm for bilateral and 4 cm for unilateral template resection. Clinical stage II and III were present in 31% and 69% of patients, respectively. Median follow-up was 14.5 months (IQR 3.3 e 37.6). Recurrences were observed in 5 and 18 patients for the unilateral and bilateral approach, respectively. Only five recurrences occurred in the retroperitoneum, 3 in-field and 1 outside-field recurrence after a bilateral approach, and only one outside field in a template approach. The 1-and 2-year recurrence-free survival rates were 91% and 91%, 77% and 72% for patients treated with unilateral template and bilateral resection, respectively (p<0.0008). Median time to recurrence was 9.5 and 9 months in template and bilateral PC-RPLND group, respectively.
As expected, adjunctive procedures were performed in 56 patients (33%) and were significantly more frequent in bilateral PC-RPLND group (44% vs. 22%, p<0.002). High-grade complication rate (Clavien-Dindo ! III) was 3% and 9% in unilateral template and bilateral PC-RPLND group, respectively (p[0.2). In 87% and 44% nervesparing was achieved in unilateral and bilateral approaches, respectively. In patients with complete follow-up data, the preservation rate of antegrade ejaculation was significantly higher in the unilateral group.
CONCLUSIONS: Unilateral template PC-RPLND in the 1st line setting is oncologically safe when the residual mass is < 5 cm. Nervesparing and preservation of antegrade ejaculation with a unilateral resection is significantly better.
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MP73-02 A SELECTIVE LYSINE-SPECIFIC DEMETHYLASE 1 INHIBITOR SUPPRESSES TESTICULAR TUMOR PROLIFERATION
Toshiki Etani*, Taku Naiki, Satoshi Nozaki, Takashi Nagai, Keitaro Iida, Ryosuke Ando, Noriyasu Kawai, Satoru Takahashi, Nagoya, Japan; Takayoshi Suzuki, Kyoto, Japan; Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: Lysine-specific demethylase 1 (LSD1), the first histone demethylase to be discovered, is a novel tesuticular tumor therapy target. NCL1 and NCD38, novel selective cell-active inhibitors of LSD1, were discovered at our university. We analyzed the efficacy of LSD1 inhibitors in tesuticular tumor in vitro and in vivo.
METHODS: Various tests were used to confirm the pathways responsible for germ cell tumor growth, and to characterize the anticancer effects of NCL1 and NCD38. Cell viability was assessed using a WST-8 assay with standard vehicle or NCL1 and NCD38 in NTERA2 and Tera-1 cells (human testicular embryonal carcinoma cell lines). Flow cytometry and western blotting were performed to assess the status of apoptosis and cell cycle in NCL1-and NCD38-treated NTERA2 cells. Mice injected with subcutaneous NTERA2 cell-derived tumors were injected intraperitoneally with vehicle or NCL1 and NCD38 twice a week, and tumor growth was monitored. Finally, tissue arrays were prepared from formalin-fixed, paraffin-embedded tissue specimens of 35 seminoma patients who underwent orchiectomy.
RESULTS: The WST assay revealed a reduction in the number of viable cells after NCL1 and NCD38 treatment in a dose-dependent manner in both cell lines. Western blotting confirmed that NCL1 and NCD38 treatment induced caspase-dependent apoptosis, and that Oct4 and SOX2 expression decreased. Flow cytometry confirmed that NCL1 and NCD38 significantly induced apoptosis in a dosedependent manner. Subcutaneous tumor volume was significantly lower in mice treated with NCL1 and NCD38 than in controls. TUNEL analysis showed that NCL1 and NCD38 treatment induced apoptosis in NTERA2 subcutaneous tumors. No adverse effect was observed with regard to body weight, blood toxicity, or the gross morphology of several organs in mice. Tissue array analysis showed that LSD1 expression in human seminoma specimens was significantly higher than that in noncancerous specimens.
CONCLUSIONS: Germ cell tumor growth was effectively suppressed with NCL1 and NCD38 both in vitro and in vivo in the absence of adverse events. The drugs act via induction of apoptosis and the suppression of SOX2 and OCT4, indicating the potential of these inhibitors as therapeutic agents for germ cell tumor.
